Related Experiment Video
Updated: Nov 23, 2025
Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
Nanomedicine: A Useful Tool against Glioma Stem Cells
Elia Bozzato1, Chiara Bastiancich2, Véronique Préat1
1Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute, Université Catholique de Louvain, 1200 Brussels, Belgium.
Abstract:
The standard of care therapy of glioblastoma (GBM) includes invasive surgical resection, followed by radiotherapy and concomitant chemotherapy. However, this therapy has limited success, and the prognosis for GBM patients is very poor. Although many factors may contribute to the failure of current treatments, one of the main causes of GBM recurrences are glioma stem cells (GSCs). This review focuses on nanomedicine strategies that have been developed to eliminate GSCs and the benefits that they have brought to the fight against cancer. The first section describes the characteristics of GSCs and the chemotherapeutic strategies that have been used to selectively kill them. The second section outlines the nano-based delivery systems that have been developed to act against GSCs by dividing them into nontargeted and targeted nanocarriers. We also highlight the advantages of nanomedicine compared to conventional chemotherapy and examine the different targeting strategies that have been employed. The results achieved thus far are encouraging for the pursuit of effective strategies for the eradication of GSCs.
Insights
Nanomedicine offers promising strategies to eliminate glioma stem cells (GSCs), a key cause of glioblastoma (GBM) recurrence. This review explores nanocarrier systems designed to target and eradicate these cancer stem cells, improving treatment efficacy.
Area of Science:
- Oncology
- Nanomedicine
- Biotechnology
Background:
- Glioblastoma (GBM) standard therapy (surgery, radiotherapy, chemotherapy) shows limited success.
- Glioma stem cells (GSCs) are a major cause of GBM recurrence and treatment failure.
- Current treatments often fail to eradicate GSCs, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review nanomedicine strategies for eliminating glioma stem cells (GSCs).
- To highlight the advantages of nanomedicine over conventional chemotherapy for GBM treatment.
- To examine targeted and nontargeted nanocarrier systems against GSCs.
Main Methods:
- Review of scientific literature on nanomedicine and GSC targeting.
- Analysis of GSC characteristics and existing chemotherapeutic strategies.
- Categorization of nanocarriers into targeted and nontargeted systems.
Main Results:
- Nanomedicine presents effective strategies for targeting and eliminating GSCs.
- Targeted nanocarriers demonstrate enhanced efficacy compared to conventional chemotherapy.
- Various targeting strategies are being employed to improve GSC eradication.
Conclusions:
- Nanomedicine holds significant promise for overcoming GBM recurrence by targeting GSCs.
- The development of advanced nanocarrier systems offers a more effective approach to cancer stem cell eradication.
- Further research into nanomedicine strategies is crucial for improving glioblastoma patient outcomes.
